Broadfin Capital’s Globus Medical GMED Stock Holding History

Broadfin Capital’s Portfolio GMED Stock Details GMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-66,700	Closed	-$2.21M	–	50
2017 Q2	$2.21M	Buy	+66,700	New	+$2.09M	0.27%	47
2013 Q4	–	Sell	-248,767	Closed	-$4.34M	–	63
2013 Q3	$4.34M	Hold	248,767	–	–	0.77%	34
2013 Q2	$4.19M	Buy	+248,767	New	+$3.84M	0.82%	30

Other funds holding GMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VBA

Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Broadfin Capital's GMED Position: Q3 2017 in Review

Broadfin Capital sold out of Globus Medical (GMED) in Q3 2017, closing a stake of 66,700 shares — an estimated $2.21M sold.

Broadfin Capital first reported a position in GMED in Q2 2013 and held it in 3 quarters. The position peaked at $4.34M in Q3 2013. 253 funds tracked by Wall St. Rank hold GMED as of Q3 2017.

Broadfin Capital reported no remaining Globus Medical position as of Q3 2017 after selling out during the quarter.
Broadfin Capital sold 66,700 Globus Medical shares in Q3 2017, an estimated $2.21M.
Broadfin Capital first reported a position in Globus Medical in Q2 2013 and held it in 3 quarters.
Broadfin Capital's Globus Medical position peaked at $4.34M in Q3 2013.
253 funds tracked by Wall St. Rank held Globus Medical as of Q3 2017.

Based on Broadfin Capital's 13F filing for Q3 2017, filed 14 Nov 2017.